ALDVI.PA Advicenne

Healthcare Biotechnology Euronext Paris
0.6300 EUR
Close of Nov 7, 2026
0.6090 2.35
Market cap
EUR 9.60M
P/E
9.0x
P/B
131.47x
ROE
-
Dividend yield
-
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALDVI.PA undervalued?

Graham number

The Graham number of Advicenne cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Advicenne fundamental analysis

6 of 11 checks passed

ROE 2/2

ROE surpassing expectations (222.59%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

ROA 0/2

The stock's ROA (-81.22%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

With a remarkably low PBV ratio (-1.74x), the stock offers substantial upside potential at a bargain price.

DER 2/2

The stock has a minimal amount of debt (-177%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 1/2

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

Net Profit Growth 1/2

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

Assets Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Graham Number 1/1

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

Dividend Growth 0/2

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Advicenne stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizur…

Full company profile